All Novel foods articles
-
Comment and Opinion
FSA causes confusion with its new CBD guidance… again
The maximum daily dosage has suddenly and unexpectedly been reduced from 70mg to just 10mg
-
News
New demands for legal clarity on CBD sales
The #SaveOurCBD campaign warned further delays to regulation would cause “an existential threat” to producers
-
Analysis and Features
How the FSA's novel foods rule could shake up the road to bug burgers
The FSA has mooted a number of new ideas in its regime review
-
News
Government mulls fast-track for lab-grown meat approval
It comes amid fears that existing restrictions on so-called novel foods are holding back firms from investing in solutions to the environmental and hunger crisis
-
Comment and Opinion
Europe must speed up the route to market for novel food technologies
Food innovations are crucial to feeding a growing population in a healthy and sustainable manner, says Sue Garfitt, CEO of The Protein Brewery
-
News
Chill Brands raises £2.6m to develop CBD vapes
International CBD group Chill Brands said the money would also fund a marketing drive for its e-commerce site
-
News
Mola and Pause add CBD soft drinks under novel foods exemption
It comes as thousands of CBD novel food applications are set to be validated by the FSA
-
Analysis and Features
Should the FSA standardise the safe daily CBD dosage?
The Food Standards Agency seems unlikely to recommend specific dosage levels
-
News
FSA set to validate thousands of CBD products
Groups responsible for half of the CBD public list confirm an update is imminent
-
Comment and Opinion
From lab-grown meat to insects, alternative proteins are the future of our diets
Alternative proteins face regulatory hurdles but applications are already in progress around the world, say Katrina Anderson, associate director and Sian Edmonds, senior associate at Osborne Clarke
-
News
Holland & Barrett delists CBD tea due to ‘faulty’ Trading Standards report
The retailer told Tea+ its CBD Tea had been pulled from sale and much of the stock quarantined in January
-
Reports
Four post-Brexit innovation foods in the pipeline
Singapore became the first country to approve meat grown from cultured cells in 2021. No applications have been made in the EU, despite it being home to much of the technological development taking place
-
Analysis and Features
What we could do with food since Brexit that we couldn’t in the EU...
The UK’s novel foods approval process currently matches the EU’s: lengthy and complicated. Could the FSA’s new, Singapore-inspired approach cut red tape and allow British innovation to thrive?
-
Analysis and Features
Are CBD brand casualties a necessary evil for investor confidence?
The FSA’s whitelist of tradeable products has led to many brands running into trouble. Even backing by David Beckham can’t guarantee longevity
-
News
Cellular share prices plummet causes Cannaray deal to falls through
CBD supplier Cannaray has cancelled its £18.6m reverse takeover of Cellular Goods due to a drop in the target’s share price
-
News
FSA strikes 300 products of CBD brand from tradeable list
More than 300 products by 1 Step were removed from the agency’s list of tradeable goods
-
News
UK genetic tech push now influencing EU GM lobbying, campaigners say
‘Vested interests’ are driving legislation in Britain and on the continent, according to research by campaign group Corporate Europe Observatory
-
Comment and Opinion
It’s Claudia Winkleman 1 David Beckham 0 in battle of the CBD brands
Even with David Beckham in its team, luck deserted Cellular Goods, leaving Cannaray with an open goal
-
News
City snapshot: EG Group revenues mount but profits hit by inflationary pressures
Forecourt giant EG Group has announced “resilient” second quarter trading, with sales rebounding by 34%, though inflationary pressures reduced headline profits. Plus, Reckitt CEO Laxman Narasimhan to take over at Starbucks and all the rest of the latest news from the City.
-
Analysis and Features
Can gene editing ease the cost of living crisis?
The UK is breaking from the EU to press ahead with gene editing. Could it cut costs on shelves? And is it even worth the risk?